Schizophrenia trials in Hungary
7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Where
- Budapest, Gyula, Szeged
- Age
- 5 years to 17 years
- People
- 400 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT07424404 · EU 2025-524062-16-00 - Phase 3Taking peopleEvenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
- Where
- Budapest, Győr, Nyíregyháza, Szombathely
- Age
- 18 years and over
- People
- 135 worldwide
- Run by
- Newron Pharmaceuticals S.p.A.
See details and how to join2024-519836-18-00 · EU 2024-519836-18-00 - Phase 3Taking peopleA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Budapest, Budapest XII, Gyongyos, Pécs
- Age
- 55 years to 90 years
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Where
- Gyongyos, Pécs
- Age
- 55 years to 90 years
- People
- 300 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00 - Phase 3Taking peopleNBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Where
- Budapest, Gyongyos, Győr
- Age
- 18 years to 65 years
- People
- 284 worldwide
- Run by
- Neurocrine Biosciences
See details and how to joinNCT07105098 · EU 2025-521215-39-00 - Phase 3Taking peopleNBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Where
- Budapest, Budapest III, Gyongyos
- Age
- 18 years to 65 years
- People
- 600 worldwide
- Run by
- Neurocrine Biosciences
See details and how to joinNCT07114874 · EU 2025-521216-19-00 - Phase 2Enrolling by invitationAn Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
- Where
- Gyongyos, Pécs
- Age
- 55 years to 91 years
- People
- 210 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00